ORIC? Executive Director & Head of Chemistry, Anthony Romero, Ph.D., will discuss the discovery of ORIC-114, our brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, at the American Chemical Society (ACS) Spring 2025 Meeting & Expo. The oral presentation will take place in the First Time Disclosures session on Wednesday, March 26, 2025, at 3:05 p.m. PT. Learn more here: https://bit.ly/3wiP6OF #ACSSpring2025
ORIC Pharmaceuticals Inc.
生物技术研究
South San Francisco，California 7,457 位关注者
Overcoming Resistance In Cancer
关于我们
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
- 网站
-
https://oricpharma.com/
ORIC Pharmaceuticals Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，California
- 类型
- 上市公司
- 创立
- 2014
- 领域
- Cancer Resistance、Immunotherapy和Oncology
地点
ORIC Pharmaceuticals Inc.员工
动态
-
On International Women's Day, we honor the remarkable women at ORIC? who are pioneering advancements in cancer therapy. Their dedication and innovation are instrumental in overcoming cancer resistance and improving patient outcomes. Thank you for inspiring us all. #IWD2025
-
On this Employee Appreciation Day, we honor our diverse team dedicated to overcoming cancer resistance. Your unwavering commitment to improving patients' lives, pursuit of excellence, and respect for one another create an environment where innovation thrives. Thank you for embodying our core values every day. #EmployeeAppreciationDay?
-
-
ORIC? President and Chief Executive Officer Jacob Chacko, M.D., and Chief Financial Officer Dominic Piscitelli will be available for one-on-one meetings at the Jefferies Biotech on the Beach Summit in Miami, FL on Wednesday, March 12, 2025. If you're attending, we welcome the opportunity to connect.
-
-
Today, we announced focused registrational clinical development plans for our two lead programs, ORIC-944 and ORIC-114, an extension of our projected cash runway into 2027, and accelerated and augmented corporate milestones. Learn more about what’s ahead:?https://bit.ly/3XjovvE
-
-
This #CancerPreventionMonth, we’re reminded that prevention starts with awareness. Regular screenings, healthy lifestyle choices, and early detection can help reduce cancer risk and save lives. At ORIC?, we’re committed to innovative research to better understand cancer while advancing therapies that potentially overcome resistance in cancer for a healthier future.?
-
-
This Black History Month, we honor the contributions of Black scientists, healthcare leaders, and advocates who have shaped cancer research and medical innovation. At ORIC?, our core values include being inclusive and inquisitive—because innovation in medicine thrives when all voices are heard. #BlackHistoryMonth #DiversityInSTEM #HealthEquity
-
-
In 2024, ORIC? made significant advancements including the initiation of multiple cohorts across both ORIC-114 and ORIC-944 programs, three strategic partnerships with major pharma companies and much more. In 2025, we remain focused on generating additional clinical evidence to further advance these promising investigational therapies as we move towards registrational studies. Learn more about our recent milestones and what’s ahead in the year to come:?https://bit.ly/4h35rZL
-
-
At ORIC?, we’re proud to have incredible women leaders and scientists driving innovation in biotech. On this International Day of Women and Girls in Science, we celebrate their contributions and the importance of empowering the next generation of women in STEM. By fostering inclusivity and opportunity, we can shape the future of science and medicine together. Here’s to breaking barriers and inspiring more women and girls to lead in STEM! #WomenInScience #GirlsInSTEM #WomenInBiotech
-
ORIC? Chief Financial Officer Dominic Piscitelli and Chief Business Officer Matt Panuwat will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference tomorrow, February 11, 2025, at 12:00 p.m. ET. Listen to the live or archived discussion to learn the latest company updates here: https://bit.ly/3VxP4tj
-